Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 4/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3458617 | 0.87 | EGFR (0.49) | EGFRKDRFLT1CDK1SYK | |
| SCHEMBL12612614 | 0.82 | PIN1 (0.58) | EGFRKDRFLT1CDK1SYK | |
| SCHEMBL15639737 | 0.82 | MKNK1 (0.55) | EGFRKDRFLT1PRKCQJAK3 | |
| SCHEMBL264886 | 0.77 | GRM4 (0.48) | EGFRSYKJAK1MEN1KMT2A | |
| SCHEMBL30306442 | 0.77 | STK17A (0.53) | EGFRSYKMEN1KMT2AAURKA | |
| SCHEMBL265799 | 0.77 | STK17A (0.53) | EGFRSYKMEN1KMT2AAURKA | |
| SCHEMBL879559 | 0.77 | ROCK2 (0.52) | EGFRKDRFLT1CDK1SYK | |
| SCHEMBL340018 | 0.77 | JAK1 (0.61) | SYKJAK1JAK3 | |
| SCHEMBL26394814 | 0.76 | PDGFRB (0.56) | KDRSYKMEN1KMT2A | |
| SCHEMBL12277575 | 0.75 | AURKA (0.51) | EGFRSYKMEN1KMT2AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688883-B1 | PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2688883-B1 | PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2016-05-18 | — | — | EP | disclosed |
| US-9006241-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-9006241-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-04-14 | — | — | US | disclosed |
| US-20140045845-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045845-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2014-02-13 | — | — | US | disclosed |
| EP-2688883-A1 | NOVEL PYRIMIDINE DERIVATIVES | Chemilia AB (SE) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012127032-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2012-09-27 | — | — | WO | disclosed |
| EP-2502924-A1 | Novel pyrimidine derivatives | Chemilia AB (SE) | 2012-09-26 | — | — | EP | disclosed |
| EP-2433636-A1 | Treatment of Malignant Diseases | Medizinische Universität Wien (AT) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045845-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMS, DPYD, TYMP | EGFR 2266/4885KDR 2073/4885FLT1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.